Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244309 · ClinicalTrials.gov registry record · Phase 3
Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
A Phase 3 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT00244309 is a Phase 3 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 348 participants.
The verdict
NCT00244309, a Phase 3 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or another drug named dutasteride (Avodart), or a combination of these two drugs is effective in improving urinary symptoms and decreasing the rate of intermittent self-catheterization after prostate brachytherapy.
Interventions
- DRUG tamsulosin and/or dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244309
The ClinicalTrials.gov registry entry for NCT00244309 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tamsulosin and/or dutasteride is the first listed.
NCT00244309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244309 about?
NCT00244309 is a clinical study titled "Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer". The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or another drug named dutasteride (Avodart), or a combination of these two drugs is effective in improving urinary symptoms and decreasing the rate of intermittent self-catheterization after prostate brachytherapy.
What is the current status of trial NCT00244309?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2005-11. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00244309?
The interventions under investigation include: tamsulosin and/or dutasteride (DRUG).
Who is sponsoring clinical trial NCT00244309?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.